Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

Overview of attention for article published in Cancer Research, February 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 7 news stories from 3 outlets.

During a continuing medical education activity hosted by PER, Paolo Tarantino, MD, discussed HER2-low breast cancer and…

By Clinical Content Hub Hope S. Rugo, MDHelen Diller Family Comprehensive Cancer Center, University of California San Francisco…

Jorge S. Reis-Filho, MD, PhD, FRCPath For the past several decades, pathologists have worked to develop optimal methods to…

Following the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Sara A.

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 3 additional news stories.